Progestogen safety and tolerance in hormonal replacement therapy.

Area of Science:

• Reproductive endocrinology and women's health.
• Pharmacology of hormone replacement therapy.

Background:

• Combined hormone therapy (estrogen plus progestogen) is standard for menopausal women with a uterus.
• The Women's Health Initiative (WHI) study indicated increased risks with conjugated equine estrogen plus medroxyprogesterone acetate (MPA).
• Risks observed with MPA were incorrectly generalized to all progestogens, despite limited comparative data.

Purpose of the Study:

• To review progestogen tolerance and side effects in hormone therapy.
• To evaluate the safety profiles of different progestogens used in hormone therapy.

Main Methods:

• Limited literature search of PubMed, Cochrane Library, ECRI, and health technology agencies.
• Review of clinical studies, observational data, and in vitro/animal studies.

Main Results:

• Existing data on progestogen side effects is often based on limited evidence.
• No long-term, double-blind trials directly compare breast cancer and cardiovascular risks among different progestogens.
• Micronized progesterone and dydrogesterone show promise as safer progestogens with favorable metabolic profiles in short-term studies.

Conclusions:

• The extrapolation of MPA-related risks to all progestogens is not fully supported by current evidence.
• Micronized progesterone and dydrogesterone appear to be safer alternatives for hormone therapy.
• Further research, including long-term comparative trials, is needed to definitively establish the safety of various progestogens.